Keyword: Novavax

Novavax’s RSV shot missed another phase 3 trial, causing the company’s stock price to lose about two-thirds of its remaining value premarket.

Jnana’s Joanne Kotz to be CEO; BioCardia brings on new clinical VP for phase 3; and Biomatics recruits biopharma veterans for $300M healthcare fund.

Andrew Witty will lead Optum as CEO, Novartis' operations lead André Wyss steps down, Gilead bids farewell to longtime R&D lead Norbert Bischofberger.

Gilead boosted oncology chief Riva to EVP, Moderna lost three top R&D officials, Bayer poached Pfizer's consumer marketing vet and more.

A team led by Washington University in St. Louis has unraveled the structure of a protein that allows RSV to elude the immune system.

Scott Gottlieb was confirmed to lead FDA, neuroscientist Thomas Insel left Verily, Immunomedics' CEO and CSO stepped down.

Sanofi has paid €120 million upfront and committed to up to €495 million more for a stake in AstraZeneca’s experimental monoclonal antibody against RSV.

Two months ago Novavax announced that its Phase III RSV F vaccine flopped fantastically, and now, with a sense of inevitability, it has announced a “corporate restructure.”

Novavax saw its shares plummet afterhours yesterday when it announced a late-stage test of its infectious respiratory disease vaccine missed all of its marks across the 12,000-strong study.